CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL-Reference-Cited by-同舟云学术

CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL

Published:2023-10-13 Issue:20 Volume:7 Page:6320-6324
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Epperly Rebecca¹^ORCID,Shulkin Barry L.²,Bag Asim K.²,Cheng Cheng³,Inaba Hiroto⁴,Lucas John T.⁵,Naik Swati¹,Triplett Brandon M.¹^ORCID,Gottschalk Stephen¹^ORCID,Talleur Aimee C.¹^ORCID

Affiliation:

1. 1Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN

2. 2Department of Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, TN

3. 3Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN

4. 4Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN

5. 5Department of Radiation Oncology, St. Jude Children’s Research Hospital, Memphis, TN

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/20/6320/2085334/blooda_adv-2023-010461-main.pdf

Reference24 articles.

1. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N Engl J Med,2018

2. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults;Gardner;Blood,2017

3. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium report;Schultz;J Clin Oncol,2022

4. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL;Talleur;Blood Adv,2022

5. Chimeric antigen receptor T cell therapy in patients with multiply relapsed or refractory extramedullary leukemia;Rubinstein;Biol Blood Marrow Transplant,2020